Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1621 to 1635 of 2185 results for guidelines

  1. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (CG68)

    This guideline has been updated and replaced by NICE guideline NG128.

  2. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

  3. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

  4. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

  5. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

  6. Obesity: working with local communities (PH42)

    This guideline has been updated and replaced by NICE guideline NG246.

  7. Weight management: lifestyle services for overweight or obese children and young people (PH47)

    This guideline has been updated and replaced by NICE guideline NG246.

  8. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

  9. Preventing excess weight gain (NG7)

    This guideline has been updated and replaced by NICE guideline NG246.

  10. Intrapartum care for healthy women and babies (CG190)

    This guideline has been updated and replaced by the NICE guideline on intrapartum care (NG235).

  11. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  12. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].